While clinical studies further confirmed the high expression of EZH2 in AML patients as well as its correlation with poor outcomes, including lower complete remission (CR) rates, higher rates of refractory/relapsed disease and shorter overall survival (OS) (Yang et al., 2022). The gene discussed is EZH2; the disease is acute myeloid leukemia.